Systemic Antifungals Market Size, Share, By Drug Classes (Azoles, Echinocandins, Polyenes, and Others), Indication (Aspergillosis, Histoplasmosis, Gastrointestinal Candidiasis, Blastomycosis, Fungal Endocarditis, and Others), End-Users (Hospital & Specialty Clinics, Ambulatory Surgical Centers, Research Institute & Clinical Trial Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America dominates the systemic antifungals market with 40.5%, due to several key factors such as high prevalence of fungal infections, strong pharmaceutical industry & R&D investments, high healthcare spending & favorable reimbursement policies, rise in antifungal resistance, increasing cases of hospital-acquired infections (HAIS), and the rest.

Asia Pacific holds the second-largest share in the systemic antifungals market due to several key factors including rising prevalence of fungal infections, increasing incidence of antifungal resistance, expanding healthcare infrastructure, high ICU & ventilator-associated fungal infections, government & private sector investments in R&D and so forth.